The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Big FDA review coming this July. Here's what athletes and patients should know about BPC 157, TB 500, and the broader peptide conversation. Always speak with your physician before starting any new protocol. #bpc157 # BPC 157 has already hit the mainstream, but should it hit your bloodstream? Gray Market Peptides: So Much Hype, So Little Data